CSTL vs NTRA
CSTL: Castle Biosciences provides specialized molecular diagnostic tests to improve risk stratification and personalized treatment decisions for patients with skin cancers, Barrett's esophagus, and atopic dermatitis. NTRA: Natera uses proprietary blood-based cell-free DNA technology to deliver personalized genetic diagnostics for oncology, prenatal screening, and organ transplant health.
Side-by-side fundamentals
| Metric | CSTL | NTRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $24.81 | $264.22 | |
| Market cap as of 2026-07-23 | $749M | $37.9B | |
| PEG as of 2026-07-23 | -0.49 | -13.63 | NTRA lower |
| Net margin as of 2026-07-23 | -3.8% | -9.1% | CSTL higher |
| Gross margin as of 2026-07-23 | +77.9% | +65.1% | CSTL higher |
| Operating margin as of 2026-07-23 | -9.8% | -13.0% | CSTL higher |
| ROE as of 2026-07-23 | -2.8% | -15.1% | CSTL higher |
| ROA as of 2026-07-23 | -2.3% | -10.5% | CSTL higher |
| Debt / equity as of 2026-07-23 | 0.03 | 0.05 | CSTL lower |
| Revenue growth (YoY) as of 2026-07-23 | -2.1% | +36.6% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | +35.9% | +41.1% | NTRA higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 1.02 | 1.54 | |
| 1-year return as of 2026-07-22 close | +52.0% | +88.8% | NTRA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.